



MEDICAL TIPS

K-MET Tablets

Issue II, No.7, 2024

Impact of metformin on cardiovascular and kidney outcome based on kidney function status in type 2 diabetic patients: a multicentric, retrospective cohort study

Yi Y, et al. Scientific Reports. 2024; 14: 2081.

- Metformin is widely used in patients with type 2 diabetes (T2DM), however its effect on patients with advanced chronic kidney disease (CKD) is unclear.
- Thus, to determine the novel evidence for effects of metformin on cardiovascular events and renal disease progression the current study was conducted.
- Use of metformin in patients with newly diagnosed T2DM compared with the control (other antidiabetic agents) was associated with lower risks of overt diabetic nephropathy (DN), major adverse cardiac events (MACEs), and major adverse kidney events (MAKEs).
- For each chronic kidney stage (3A, 3B, and 4) use of metformin was associated with low risks of MACEs and MAKEs.

Use of Metformin in patients with T2DM is associated with a lower risk of overt diabetic nephropathy and major cardiovascular events and major adverse kidney events.

